ASXL1 and myeloproliferative disorder: Differences in terms of overall survival between AML‐MRC ASXL1+ versus ASXL1− patients were found only in de novo AML‐MRC patients with intermediate‐risk karyotype (excluding MDS and MDS/MPN history and adverse‐risk karyotype), having ASXL1+ patients a worst outcome with a clear trend toward statistical association than ASXL1−, HR = 2.9 P = .072 (Figure 3B).